Profile data is unavailable for this security.
About the company
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, DEXTROFEN S SYRUP 60ml, Diafac XR, Diafac 500 mg 10 tablets, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, Pehavask 5 & 10, Spirolactone 25 & 100, Dios, anemone, Pladel, and others. The Company also operates calibration laboratory. It offers medicines for cardiovascular & hematopoietic, gastrointestinal & hepatobiliary, hormone Genito, urinary endocrine & metabolic, vitamins & minerals nutrition, dermatology, local anesthesia, immune & allergy, and others.
- Revenue in IDR (TTM)1.16tn
- Net income in IDR17.31bn
- Incorporated--
- Employees1.55k
- LocationPhapros Tbk PTLantai Dasar, Gedung RNIJl. Denpasar Raya Kav. DIIIKuninganJAKARTA SELATAN 12950IndonesiaIDN
- Phone+62 215762709
- Fax+62 215763910
- Websitehttps://www.phapros.co.id/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phapros Tbk PT | 1.16tn | 17.31bn | 554.40bn | 1.55k | 32.03 | 0.7595 | 7.78 | 0.4776 | 20.61 | 20.61 | 1,381.79 | 869.00 | 0.606 | 1.85 | 2.00 | 695,446,600.00 | 0.8735 | -- | 1.74 | -- | 48.72 | -- | 1.44 | -- | 0.9263 | 1.40 | 0.5559 | -- | 7.23 | -- | -77.17 | -- | -- | -- |
| Albert David Ltd | 621.90bn | 68.07bn | 557.09bn | 1.33k | 8.18 | -- | 6.62 | 0.8958 | 64.17 | 64.17 | 586.38 | -- | -- | -- | -- | 2,522,751.00 | -- | 6.78 | -- | 9.20 | 64.20 | 62.24 | 10.95 | 7.24 | -- | 70.42 | -- | 17.74 | 26.70 | 0.4556 | 59.23 | 15.62 | -11.20 | 10.35 |
| KAINOS Laboratories, Inc. | 567.58bn | 64.29bn | 558.84bn | 149.00 | 7.93 | 0.7853 | 6.92 | 0.9846 | 132.79 | 132.79 | 1,178.72 | 1,340.82 | 0.6402 | 3.36 | 3.20 | 32,721,980.00 | 7.25 | 6.15 | 9.53 | 8.54 | 50.93 | 50.41 | 11.33 | 8.84 | 2.25 | -- | 0.1438 | 16.87 | 8.38 | -0.3795 | 22.74 | 10.58 | 15.02 | 14.87 |
| Lyka Labs Ltd | 197.10bn | -46.99bn | 559.51bn | 713.00 | -- | -- | -- | 2.84 | -8.83 | -8.83 | 36.63 | -- | -- | -- | -- | -- | -- | -5.49 | -- | -10.62 | 60.15 | 58.55 | -23.72 | -12.22 | -- | 0.50 | -- | -- | 125.02 | 10.71 | 437.53 | -- | -10.91 | -- |
| Modern Chinese Medicine Group Co Ltd | 856.55bn | 194.85bn | 574.73bn | 186.00 | 2.94 | 0.6813 | 2.81 | 0.671 | 0.1669 | 0.1669 | 0.734 | 0.7192 | 0.9914 | 7.23 | 4.73 | 2,235,525.00 | 22.55 | -- | 25.78 | -- | 43.17 | -- | 22.75 | -- | 6.14 | -- | 0.0004 | -- | 16.85 | -- | 28.63 | -- | -- | -- |
| Antisense Therapeutics Limited | 2.07bn | -83.25bn | 598.32bn | 8.00 | -- | 3.63 | -- | 288.50 | -0.0121 | -0.0121 | 0.0003 | 0.024 | 0.0094 | -- | 0.1917 | -- | -37.52 | -75.15 | -40.28 | -86.06 | -- | -- | -4,014.26 | -15,600.63 | -- | -670.84 | 0.0114 | -- | 717.70 | -24.59 | 27.90 | -- | -24.16 | -- |
